美股異動 | 禮來(LLY.US)終止PD-1激動劑候選藥物研究 AnaptysBio(ANAB.US)暴跌超20%

智通財經網

2024-10-30

週三，AnaptysBio(ANAB.US)股價走低，截至發稿，該股跌超20%，報24.455美元。AnaptysBio正在推進一種與禮來(LLY.US)PD-1激動劑抗體Peresolimab類似的關節炎療法，在禮來宣佈決定終止對該候選藥物的研究後，AnaptysBio股價大跌。

今年7月，H.C. Wainwright首次覆蓋AnaptysBio，給予“買入”評級和55美元的目標價。該行認爲其旗下的PD-1激動劑rosnilimab可能比peresolimab更有效。rosnilimab的試驗初步數據預計將在2025年第一季度公佈。

海量資訊、精準解讀，盡在新浪財經APP

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2479825667"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479825667\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479825667?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-10-30 22:26","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2479825667","market":"sh","top_or_hot":-1,"title":"美股異動 | 禮來(LLY.US)終止PD-1激動劑候選藥物研究 AnaptysBio(ANAB.US)暴跌超20%","media":"智通財經網","content":"<html><body><div>\n<p cms-style=\"font-L\">週三，AnaptysBio(ANAB.US)股價走低，截至發稿，該股跌超20%，報24.455美元。AnaptysBio正在推進一種與<a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY.US)PD-1激動劑抗體Peresolimab類似的關節炎療法，在禮來宣佈決定終止對該候選藥物的研究後，AnaptysBio股價大跌。</p><p cms-style=\"font-L\">今年7月，H.C. Wainwright首次覆蓋AnaptysBio，給予“買入”評級和55美元的目標價。該行認爲其旗下的PD-1激動劑rosnilimab可能比peresolimab更有效。rosnilimab的試驗初步數據預計將在2025年第一季度公佈。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股異動 | 禮來(LLY.US)終止PD-1激動劑候選藥物研究 AnaptysBio(ANAB.US)暴跌超20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股異動 | 禮來(LLY.US)終止PD-1激動劑候選藥物研究 AnaptysBio(ANAB.US)暴跌超20%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經網</strong><span class=\"h-time small\">2024-10-30 22:26</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p cms-style=\"font-L\">週三，AnaptysBio(ANAB.US)股價走低，截至發稿，該股跌超20%，報24.455美元。AnaptysBio正在推進一種與<a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY.US)PD-1激動劑抗體Peresolimab類似的關節炎療法，在禮來宣佈決定終止對該候選藥物的研究後，AnaptysBio股價大跌。</p><p cms-style=\"font-L\">今年7月，H.C. Wainwright首次覆蓋AnaptysBio，給予“買入”評級和55美元的目標價。該行認爲其旗下的PD-1激動劑rosnilimab可能比peresolimab更有效。rosnilimab的試驗初步數據預計將在2025年第一季度公佈。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml\">智通財經網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0238689110.USD","symbol_name":"貝萊德環球動力股票基金","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml","article_id":"2479825667","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479825667","pubTimestamp":1730298360,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"週三，AnaptysBio(ANAB.US)股價走低，截至發稿，該股跌超20%，報24.455美元。AnaptysBio正在推進一種與禮來(LLY.US)PD-1激動劑抗體Peresolimab類似的關節炎療法，在禮來宣佈決定終止對該候選藥物的研究後，AnaptysBio股價大跌。今年7月，H.C. Wainwright首次覆蓋AnaptysBio，給予“買入”評級和55美元的目標價。該行認為其旗下的PD-1激動劑rosnilimab可能比peresolimab更有效。rosnilimab的試驗初步數據預計將在2025年第一季度公佈。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0238689110.USD":"贝莱德环球动力股票基金","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","BK4588":"碎股","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","PD":"PagerDuty, Inc.","BK4581":"高盛持仓","LU0058720904.USD":"联博国际健康护理基金A","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","ANAB":"Anaptysbio Inc","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LLY":"礼来","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4023":"应用软件","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","BK4516":"特朗普概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4534":"瑞士信贷持仓","BK4139":"生物科技","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD"},"translate_title":"U.S. stock changes Eli Lilly (LLY.US) terminates PD-1 agonist drug candidate research AnaptysBio (ANAB.US) plummets more than 20%","themeId":"69b555e67b9b57f18da6272607047169","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":1,"LLY":1,"PD":1},"content_text":"週三，AnaptysBio(ANAB.US)股價走低，截至發稿，該股跌超20%，報24.455美元。AnaptysBio正在推進一種與禮來(LLY.US)PD-1激動劑抗體Peresolimab類似的關節炎療法，在禮來宣佈決定終止對該候選藥物的研究後，AnaptysBio股價大跌。今年7月，H.C. Wainwright首次覆蓋AnaptysBio，給予“買入”評級和55美元的目標價。該行認為其旗下的PD-1激動劑rosnilimab可能比peresolimab更有效。rosnilimab的試驗初步數據預計將在2025年第一季度公佈。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}